# Tentative Agenda July 14, 2000 Joint Meeting - Nonprescription Drugs Advisory Committee & Endocrinologic and Metabolic Advisory Committee

Food and Drug Administration
Center for Drug Evaluation and Research
Bethesday Holiday Inn, 8120 Wisconsin Avenure, Bethesda MD

# Pravacholo NDA 21-198, Pravastatin sodium, 10mg, Bristol- Myers Squibb

### 8:00 Call to Order, Introductions

Eric Brass, M.D., Chair

#### **Conflict of Interest Statement**

Sandra Titus, Ph.D., Executive Secretary, PDAC

#### Introduction to the Issues

David Orloff, M.D., Deputy director, DMEDP

## 8:15 Bristol-Myers Squibb Presentation

9:45 Break

## 10:15 FDA Presentation

## **Medical Review and Introduction**

Mary H. Parks, M.D., Medical Officer, DMEDP

#### Use Trials

Daiva Shetty, M.D., Medical Officer, DOTCDP

## Safety Concerns: Drug Interactions

Jim Wei, Ph.D., OCPB

## **Label Comprehension**

Karen Lechter, Ph.D., DDMAC

#### Summary

Linda Katz, M.D., MPH, Associate Director, DOTCDP

#### 12:00 Lunch

## 1:00 Charge to Committee

Linda Katz, M.D., MPH, Associate Director, DOTCDP

#### 1:15 Discussion and Questions

Break

## 4:30 Adjourn